Modelling the natural history of Huntington's disease progression

被引:13
|
作者
Kuan, W. L. [1 ]
Kasis, A. [2 ]
Yuan, Y. [2 ]
Mason, S. L. [1 ]
Lazar, A. S. [1 ]
Barker, R. A. [1 ]
Goncalves, J. [2 ,3 ]
机构
[1] Univ Cambridge, Dept Clin Neurosci, John van Geest Ctr Brain Repair, Cambridge, England
[2] Univ Cambridge, Dept Engn, Cambridge CB2 1PZ, England
[3] Univ Luxembourg, Luxembourg Ctr Syst Biomed, Walferdange, Belval, Luxembourg
来源
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2015年 / 86卷 / 10期
基金
英国工程与自然科学研究理事会;
关键词
CAG-REPEAT LENGTH; AGE-OF-ONSET; NEURODEGENERATIVE DISEASES; CLINICAL PROGRESSION; RATING-SCALE;
D O I
10.1136/jnnp-2014-308153
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background The lack of reliable biomarkers to track disease progression is a major problem in clinical research of chronic neurological disorders. Using Huntington's disease (HD) as an example, we describe a novel approach to model HD and show that the progression of a neurological disorder can be predicted for individual patients. Methods Starting with an initial cohort of 343 patients with HD that we have followed since 1995, we used data from 68 patients that satisfied our filtering criteria to model disease progression, based on the Unified Huntington's Disease Rating Scale (UHDRS), a measure that is routinely used in HD clinics worldwide. Results Our model was validated by: (A) extrapolating our equation to model the age of disease onset, (B) testing it on a second patient data set by loosening our filtering criteria, (C) cross-validating with a repeated random subsampling approach and (D) holdout validating with the latest clinical assessment data from the same cohort of patients. With UHDRS scores from the past four clinical visits (over a minimum span of 2 years), our model predicts disease progression of individual patients over the next 2 years with an accuracy of 89-91%. We have also provided evidence that patients with similar baseline clinical profiles can exhibit very different trajectories of disease progression. Conclusions This new model therefore has important implications for HD research, most obviously in the development of potential disease-modifying therapies. We believe that a similar approach can also be adapted to model disease progression in other chronic neurological disorders.
引用
收藏
页码:1143 / 1149
页数:7
相关论文
共 50 条
  • [11] DESIGN OF A PROSPECTIVE, LONGITUDINAL, NATURAL HISTORY STUDY IN HUNTINGTON'S DISEASE
    Hooper, Gregory
    Trundell, Dylan
    Palermo, Giuseppe
    Kremer, Thomas
    Frick, Elsbeth
    Boak, Lauren
    Doody, Rachelle
    Schobel, Scott
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 : A48 - A48
  • [12] The use of modelling in Huntington's disease
    Guest, D.
    Sathe, S.
    Sampaio, C.
    Warner, J.
    MOVEMENT DISORDERS, 2024, 39 : S668 - S668
  • [13] Therapeutic interventions for disease progression in Huntington's disease
    Mestre, Tiago
    Ferreira, Joaquim
    Coelho, Miguel M.
    Rosa, Mario
    Sampaio, Cristina
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (03):
  • [14] GENETIC MODIFIERS OF HUNTINGTON'S DISEASE PROGRESSION
    Moss, Davina Hensman
    Pardinas, Antonio
    Flower, Michael
    Miller, James
    Lo, Kitty
    Plagnol, Vincent
    Holmans, Peter
    Jones, Lesley
    Langbehn, Douglas
    Tabrizi, Sarah
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2016, 87 (12):
  • [15] Huntington's Disease Progression and Caregiver Burden
    Modrzejewska-Zielonka, Ewa
    Ren, Michal
    Mlodak, Andrzej
    Marcinkowski, Jerzy Tadeusz
    Zielonka, Daniel
    EUROPEAN NEUROLOGY, 2022, 85 (05) : 398 - 403
  • [16] GENETIC MODIFIERS OF HUNTINGTON'S DISEASE PROGRESSION
    Moss, Davina J. Hensman
    Pardinas, Antonio F.
    Flower, Michael
    Miller, James
    Lo, Kitty
    Plagnol, Vincent
    Holmans, Peter
    Jones, Lesley
    Langbehn, Douglas
    Tabrizi, Sarah J.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2016, 87 : A26 - A27
  • [17] Modeling the Full Progression of Huntington's Disease
    Shumeyko, Emma P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 100 (05) : 405 - 405
  • [18] Progression of structural neuropathology in Huntington's Disease
    Kipps, CM
    Duggins, AJ
    Mahant, N
    Ashburner, J
    Gomes, L
    McCusker, E
    NEUROLOGY, 2004, 62 (07) : A358 - A359
  • [19] Identifying modifiers of Huntington's disease progression
    Saft, Carsten
    LANCET NEUROLOGY, 2017, 16 (09): : 679 - 680
  • [20] Microglial activation and Huntington's disease progression
    Tai, Y. F.
    Pavese, N.
    Gerhard, A.
    Brooks, D. J.
    Piccini, P.
    MOVEMENT DISORDERS, 2006, 21 : S625 - S625